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694Objective: The minimally invasive, video-assisted thoracoscopic surgical (VATS) approach to resection of the
thymus is frequently practiced for benign disease; however, a VATS approach for thymoma remains controver-
sial. The objective of the present study was to evaluate the feasibility of VATS thymectomy for the treatment of
early-stage thymoma and to compare the outcomes with those after open resection.
Methods: A retrospective review of 40 patients who underwent surgical resection of early-stage thymoma
during a 12-year period was conducted. Data on patient characteristics, morbidity, recurrence, and survival
were collected. The primary endpoint studied was overall survival.
Results:Of the 40 patients, 14 underwent thymectomy for stage I and 26 for stage II thymoma; 19 were men and
21 were women (median age, 64 years; range, 35–86 years). Open thymectomy was performed in 22 patients,
and VATS was performed in 18. The operative mortality rate was 0%. The tumor stage and number of patients
undergoing adjuvant radiotherapy were comparable in both surgical groups. The median length of hospital stay
was shorter in the VATS group (3 days) than in the open group (5 days) (P¼ .0001). The median follow-up was
36 months. No significant differences were found in the estimated recurrence-free and overall 5-year survival
rates (83%–100%) between the 2 groups.
Conclusions:VATS of early-stage thymoma appears safe and feasible and was associated with a shorter hospital
stay. The oncologic outcomes were comparable in the open and VATS groups during intermediate-term
follow-up. Additional follow-up is required to evaluate the long-term results of thoracoscopic thymectomy
for early-stage thymoma. (J Thorac Cardiovasc Surg 2011;141:694-701)Tumors of the mediastinum are relatively rare.1 Thymoma
is the most common primary neoplasm of the mediastinum
in the adult population, with surgery the primary treatment
modality, except for very advanced stages.2 In approxi-
mately 30% of patients with thymoma, myasthenia gravis
(MG) is coexistent.3 Several controversies exist with regard
to thymomas, including the staging systems used, the ap-
proach to surgery, and the use of adjuvant therapy.
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The Journal of Thoracic and Cardiovascular Surgeral thoracic procedures. These have included treatment
of benign diseases and the treatment of esophageal and
lung cancer.4-8 Blalock and colleagues9 described a series
of patients with MG with improvement after thymectomy.
Since then, thymectomy has been an important component
in the management of MG.9 In patients with thymoma, sur-
gical resection with total thymectomy, performed using an
open technique, typically with a sternotomy, has been the
standard treatment. A recent systematic review of surgical
resection for thymoma reported that the 5-year overall sur-
vival rate of patients with stage I and stage II thymoma
ranged from 89% to 100% and 71% to 95%, respec-
tively.10 That review also concluded that the published
evidence comparing various approaches, in particular,
minimally invasive approaches, was insufficient with regard
to the outcomes. Although some published data are avail-
able for thoracoscopic thymectomy for nonthymoma MG,
very few data are available describing the outcomes after
minimally invasive resection of thymoma.
Theminimally invasive approaches described for the resec-
tion of thymus have included transcervical thymectomy and
video-assisted thoracoscopic thymectomy.11-14 Although
these minimally invasive thoracoscopic approaches toery c March 2011
TABLE 1. Patient characteristics
Characteristic Value
Gender (n)
Male 19
Female 21
Age (y)
Median 63
Range 35–86
Stage
Stage I 14
Stage II 26
WHO histologic type
A 6
AB 12
B1–B3 20
C 1
Not determined 1
Abbreviations and Acronyms
LOS ¼ length of stay
MG ¼ myasthenia gravis
VATS ¼ video-assisted thoracoscopic surgery
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Sresection of the thymus are frequently practiced for benign
disease, a video-assisted thoracoscopic surgical (VATS) ap-
proach for thymoma remains controversial. The primary ob-
jective of the present study was to evaluate the feasibility of
VATS thymectomy for early-stage (stage I and II) thymoma.
Our second objective was to compare the intermediate-term
outcomes of a minimally invasive approach (VATS) with
those after open resection.Surgical approach
VATS 18
Open 22
Stage and surgical approach
Stage 1
VATS 5
Open 9
Stage 2
VATS 13
Open 13
Median tumor size (cm)
VATS 3.6*
Open 6.1
Myasthenia gravis
VATS 7
Open 4
VATS, Video-assisted thoracoscopic surgical resection; WHO,World Health Organi-
zation. *P ¼ .0003.MATERIALS AND METHODS
We retrospectively reviewed our experience with thymectomy for the
treatment of early-stage (stage I and II) thymoma at the University of Pitts-
burgh (during a 12-year period 1996–2008). The institutional review board
at the University of Pittsburgh approved the study.
Patient Characteristics
A total of 40 patients who underwent thymectomy for stage I or II
thymoma were identified. Of the 40 patients, 14 had stage I thymoma
and 26 had stage II thymoma; 19 were men and 21 were women (median
age, 64 years; range, 35–86 years). Open thymectomy was performed in
22 patients, and VATS resection in 18. MG was present in 11 patients
(27.5%). The patient characteristics are summarized in Table 1.
Surgical Technique
The technique of VATS thymectomy has been previously described11-13
and can be performed with a unilateral or bilateral approach. In brief,
general endotracheal anesthesia was established with a double-lumen en-
dotracheal tube or a single-lumen tube with carbon dioxide insufflation.
For the unilateral right-sided approach, the ports were placed along the
right anterior axillary line, conforming to the mammary crease. Three
5-mm ports were placed in the third, fifth, and eighth interspaces. After
right lung isolation, the inferior portion of the thymus was mobilized.
Dissection was started in the normal thymus, away from the tumor, with
minimal manipulation of the tumor to avoid any breaches in the capsule.
It is critical that the tumor manipulation is kept to a minimum and that
the plane of dissection is kept beyond the capsule. Similarly, direct traction
by grasping the tumor should be avoided to limit capsular tears and contam-
ination locally and in the pleural space. The dissection plane was extended
cranially, taking care to preserve the integrity of the right phrenic nerve.
The left portion of the thymus was mobilized free from the pericardium
overlying the ascending aorta. The thymic veins were clipped and divided.
The right and left thymic horns were dissected free, and the specimen was
removed in a plastic retrieval bag.
Our current approach has been bilateral VATS, which promotes better
visualization of key anatomic structures and facilitates the accomplishment
of complete thymectomy. We have typically used a single-lumen tube with
carbon dioxide insufflation, with the patient in the supine position. The
procedure was begun on the left, and a similar 5-mm port arrangement
was established. The mediastinal pleura was incised just anterior to the
phrenic nerve. The base of the left thymic lobe was mobilized and retracted
superiorly. All thymic and perithymic fatty tissue was mobilized en bloc
with the specimen, allowing exposure of the underlying pericardium andThe Journal of Thoracic and Caaorta. The thymus was then carefully dissected along the innominate
vein, and the thymic tributaries were clipped and divided. The dissection
was continued to the innominate–superior vena cava junction. The cervical
horns were mobilized and swept inferiorly with the specimen. Once max-
imal mobilization was achieved on the left, the ports and instrumentation
were withdrawn. The lung was re-expanded with a red-rubber catheter po-
sitioned within the pleural space to evacuate the pneumothorax, and the
catheter was removed. Similar to the left side, 3 ports were placed on the
right side, and dissection was completed along the innominate–superior
vena cava junction, the venous thymic branches were clipped, any residual
attachments were divided, and the specimen was removed. The techniques
for open total thymectomy have been well described previously.15
Data Collection
The objective of the present study was to determine the feasibility of
a minimally invasive VATS approach for resection of early-stage thymoma
and to compare the outcomes of minimally invasive VATS resection with
those of standard open surgical resection. Information on patient demo-
graphics, co-morbidities, Charlson co-morbidity index,16 the presence of
associated MG, tumor characteristics, staging information, surgical ap-
proach, and adjuvant treatment was collected. TheMasaoka staging system
was used to define the stage I and stage II tumors.17 In patients with MG,
the Osserman score and the Myasthenia Gravis Foundation of America
scores were collected.18,19rdiovascular Surgery c Volume 141, Number 3 695
TABLE 2. Comparison of variables of VATS versus open surgical
groups
Surgery type
Variable VATS Open P value
Gender .525*
Male 10 9
Female 8 13
Median age (y) 64 64 .924y
CCI 3 2 .294y
Tumor stage .510*
I 5 9
II 13 13
Adjuvant therapy .360*
Yes 7 12
No 11 10
Margin status .196*
Positive 1 0
Negative 16 22
MG .1734*
Yes 7 4
No 11 18
Tumor size (cm) .0003y
Median 3.6 6.1
Mean 3.5 5.8
SD 1.1 2
LOS (d) .0001y
Median 3 5
Mean 2.9 6.2
SD 1.6 4.2
VATS, Video-assisted thoracoscopic surgical resection; CCI, Charlson co-morbidity
index;MG,myasthenia gravis; SD, standard deviation; LOS, length of stay. *Fisher’s
exact test. yWilcoxon test (2 tailed).
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The specific endpoints studied were perioperative complications,
recurrence-free survival, and overall survival. The primary endpoint stud-
ied was overall survival, and the secondary endpoint was recurrence-free
survival. Kaplan–Meier plots with 95% Greenwood confidence intervals
were constructed to estimate the overall survival and recurrence-free sur-
vival. Patients whowere alive at follow-up were censored from the analysis
of overall survival. Recurrence-free survival was computed as the interval
from resection to disease recurrence. For the present analysis, the patients
whowere alive at the last follow-up examination or who had died while dis-
ease free were censored. The patient characteristics in the open resection
and VATS resection groups were compared using Fisher’s exact test for cat-
egorical variables and theWilcoxon test for continuous variables. The post-
operative Osserman score was compared with the preoperative score using
the signed rank test. All tests were 2 tailed.
A 2-way factorial analysis of variance was conducted to test the interac-
tion between the surgeon and operative procedure. The analysis was
limited to surgeons who had performed more than 4 procedures. The asso-
ciation between the Charlson co-morbidity index, and length of stay (LOS)
was evaluated by testing the significance of the Spearman rank correlation
coefficient.
Propensity Score
We compared the 2 surgical procedure groups by constructing a propen-
sity score.20 The propensity score is a predicted score that is proportional to
the likelihood that, according to the covariates, a patient has been chosen
for either VATS or open surgery. The score has the tendency to equilibrate
the comparison arms in an observational study as if the treatments had been
randomly assigned. We evaluated the following candidates for their utility
in a propensity score: Charlson co-morbidity index (raw and age adjusted),
patient age and gender, tumor size and stage, date of surgery, and the pres-
ence of MG. We selected 3 covariates because of their association with the
surgical procedure group: tumor size, date of surgery, and the presence of
MG. For the evaluation of overall and recurrence-free survival, we used
Cox proportional hazards regression analysis to test the effect of the proce-
dure type, adjusting for the propensity score. To evaluate the effect on the
LOS, we applied analysis of covariance, treating the propensity score as
a continuous covariate.RESULTS
Comparison of Patient Characteristics
In the present patient cohort, 22 patients underwent open
thymectomy and 18 underwent VATS resection. The tumor
stages were comparable in the 2 surgical groups, and no sig-
nificant differences were found in the number of patients
with MG or the number receiving adjuvant therapy between
the 2 groups. The median tumor size in the VATS group was
significantly smaller than that in the open group, with a me-
dian tumor size of 3.6 cm in the VATS group and 6.1 cm in
the open group (P¼ .0003). These analyses are summarized
in Table 2.Comparison of Outcomes
The operative mortality rate was 0%. The median hospi-
tal LOSwas shorter for the VATS group (3 days) than for the
open group (5 days) (P¼ .0001) (Table 2). Significant mor-
bidity was infrequent, and the most frequent perioperative
complications were atrial fibrillation (n ¼ 2), pneumonia696 The Journal of Thoracic and Cardiovascular Surg(n ¼ 1), and respiratory insufficiency requiring ventilator
support (n ¼ 2).
Of the 40 patients, 11 hadMG, 7 in the VATS group and 4
in the open group. The MG symptoms, as assessed by the
Myasthenia Gravis Foundation of America scale, improved
in 9 of the 11 patients, were unchanged in 1, and were exac-
erbated in 1. The median modified Osserman score was 2
preoperatively. The median within-patient Osserman score
had declined by 2 points from the preoperative score at
the last follow-up assessment. This decrease (improvement)
in the Osserman score was statistically significant (signed
rank test, P ¼ .006). No differences between the 2 surgical
approaches and the improvement in Osserman score were
noted.Overall Survival
No procedure-related mortalities occurred. During the
follow-up period, 3 patients died. The median follow-up
for the remaining patients was 36 months (58 months for
the open group and 27 months for the VATS group). The
minimally invasive techniquewas introduced later in our se-
ries, resulting in the shorter median follow-up for the VATS
group. The estimated probability of 5-year overall survivalery c March 2011
Years After Thymectomy
Su
rv
iva
l P
ro
ba
bi
lity
0 1 2 3 4 5 6 7 8 9 10
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
40 35 26 19 17 15 8 7 3 3 2
FIGURE 1. Kaplan–Meier plot illustrating overall survival for entire group, with confidence limits. Time, in years, from thymectomy plotted on x-axis.
Dotted lines indicate 95% confidence bands for probability of overall survival. Numbers at risk shown above x-axis.
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Sfor the entire cohort was 93% (95% confidence interval,
74%–98%) (Figure 1). When the surgical approaches
were compared, the probability of estimated 5-year overall
survival was 100% for the VATS group and 88% (95% con-
fidence interval 59–97%) for the open group (P ¼ .949).
There was no significant difference in overall survival
when the surgical approach was stratified by tumor stage.
Recurrence-Free Survival
During follow-up, 1 patient developed a recurrence. The
estimated probability of 5-year recurrence-free survival forYears Afte
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FIGURE 2. Kaplan–Meier plot illustrating recurrence-free survival for entire g
x-axis. Dotted lines indicate 95% confidence bands for probability of recurren
The Journal of Thoracic and Cathe entire cohort was 93% (95% confidence interval,
59%–99%) (Figure 2). When the surgical approaches
were compared, the estimated 5-year recurrence-free
survival rate was 100% for the VATS group and 83%
(95% confidence interval, 27%–88%) for the open group
(P ¼ .602) (Figure 3, A). There were no significant differ-
ences in recurrence-free survival when the surgical ap-
proach was stratified by tumor stage. Figure 3, B and C,
depicts the results of estimated recurrence-free survival of
patients with stage I and stage II thymoma, stratified by
the surgical approach.r Thymectomy
5 6 7 8 9 10
9 4 3 1 1 1
roup, with confidence limits. Time, in years, from thymectomy plotted on
ce-free survival. Numbers at risk shown above x-axis.
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FIGURE 3. A, Kaplan–Meier plot illustrating recurrence-free survival
stratified by group (thoracoscopic vs open). Time, in years, from thymec-
tomy plotted on x-axis. B, Kaplan–Meier plot illustrating recurrence-free
survival for patients with stage I thymoma stratified by group (thoraco-
scopic vs open). Time, in years, from thymectomy plotted on x-axis. Num-
bers at risk shown above x-axis. C, Kaplan–Meier plot illustrating
recurrence-free survival for patients with stage II thymoma stratified by
group (thoracoscopic vs open). Time, in years, from thymectomy plotted
on x-axis. Numbers at risk shown above x-axis.
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Five surgeons performedmost of the operations, and each
performed 4 or more procedures. Of the 5 surgeons, 4 per-
formed both VATS and open resection, and 1 surgeon exclu-698 The Journal of Thoracic and Cardiovascular Surgsively performed open resection. The median LOS of
patients treated by the busier surgeons showed that an
open approach was associated with a longer LOS. A 2-
way factorial analysis of variance was conducted to test
the interaction between surgeon and operative procedure
among the surgeons who performed most of the procedures.
This test of interaction indicated that no interaction was
present between the surgeon and procedure type (ie, the effect
of the procedure was independent of the surgeon performing
the procedure). Among the 4 busy surgeons who did both
procedures, the LOS was consistently longer for those pa-
tients undergoing open resection comparedwith those under-
going the VATS approach (P ¼ .042). Therefore, it appears
that the LOS was not confounded by surgeon preference
and was likely a true difference, reflecting the potentially
shorter recovery time associated with a VATS approach.
As listed in Table 2, no significant differences were found
in the co-morbidities between the 2 groups (median Charl-
son co-morbidity index score of 2 for the open group vs
3 for the VATS group, P ¼ .294). The LOS was not associ-
ated with the Charlson co-morbidity index, as evaluated by
testing the significance of the Spearman rank correlation
coefficient (correlation ¼ .023, P ¼ .884).Comparison of Surgical Approaches by Propensity
Score
We compared the 2 surgical procedure groups with the
aid of a propensity score. We evaluated the following can-
didates for their utility in the propensity score: Charlson
co-morbidity index (raw and age adjusted), patient age
and gender, tumor size and stage, date of surgery, and the
presence of MG. Three covariates were selected because
of their association with the surgical procedure groups: tu-
mor size, date of surgery, and the presence of MG. No dif-
ferences were found in overall survival, adjusting for the
propensity score. In addition, no differences were found
in recurrence-free survival, adjusting for the propensity
score. The propensity score was independent of the LOS,
and an analysis of covariance for the effect of surgical ap-
proach on the LOS remained significant (P¼ .0043, adjust-
ing for propensity score).DISCUSSION
Open surgical resection has been the standard treatment of
patients with early-stage thymoma. In patients with MG, the
approaches and extent of resection have been debated in pub-
lished reports. These approaches have included transcervical
thymectomy, trans-sternal thymectomy, video-assisted thor-
acoscopic thymectomy, and ‘‘maximal thymectomy,’’ with
separate sternal and cervical incisions.14,21-25 Minimally
invasive approaches, including a transcervical approach
and a VATS approach, have been described for thymoma;
however, minimal data are available from publishedery c March 2011
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thymoma using these approaches.
In the present series, we analyzed 40 patients who had un-
dergone resection for early-stage thymoma. Approximately
one half of the patients had undergone total thymectomy us-
ing a VATS approach and one half had undergone resection
with an open technique. This is the largest series of the
published studies to our knowledge to compare these
techniques for the treatment of thymoma. We found that
minimally invasive VATS resection is safe and feasible. In
addition, it was associated with a shorter hospital LOS.
The oncologic outcomes were comparable between the
open and VATS groups during intermediate-term follow-
up. The present study primarily demonstrates the feasibility
of a minimally invasive VATS approach for the resection of
thymoma. It is important, however, to emphasize that
thymoma is an indolent disease, and longer follow-up is
required to evaluate and compare the oncologic outcomes.
Minimally Invasive Approaches to Thymectomy
Meyer and colleagues24 presented their results from
a comparative study of trans-sternal versus minimally inva-
sive thymectomy for patients with MG, primarily nonthy-
moma MG. A total of 48 patients underwent thymectomy
with a minimally invasive approach and 47 patients with
a trans-sternal approach. The series by Meyer and col-
leagues24 included 10 patients with thymoma, 4 in the
VATS group and 6 in the open group. Similar to the results
from the present study, Meyer and colleagues24 noted a sig-
nificant difference in the hospital LOS, favoring the mini-
mally invasive group (1.9 vs 4 days). The 2 groups had
equivalent improvement in the symptoms of MG. These in-
vestigators concluded that thymectomy was effective in
MG, regardless of the surgical approach. Bachmann and col-
leagues25 compared the outcomes of thoracoscopic (n¼ 22)
and open (n¼ 106) thymectomy in patientswithMG. In their
series, 27 patients had thymoma. Similar to our series, the
hospital LOS was shorter with the thoracoscopic approach.
Transcervical thymectomy is another minimally invasive
approach for the resection of the thymus.14,23 However, its
use in patients with thymoma has also been controversial.
One of the largest experiences was reported by Papatestas
and colleagues26 of 46 patients with occult thymoma.
More recently, Deeb and colleagues27 reported a series of
9 patients with thymoma who had undergone successful
transcervical thymectomy. At a mean follow-up of 48
months, no recurrences had developed.
Length of Stay
In this study, we found that a minimally invasive VATS
approach is associated with a shorter LOS in the hospital
when compared with an open approach. There are, however,
several confounding variables when analyzing the LOS in
the hospital, and the LOS is not likely to be solely depen-The Journal of Thoracic and Cadent on a single factor such as the surgical approach. These
potential factors that can contribute to the LOS include se-
lection bias, the experience and preference of the surgeon,
patient co-morbidities, perioperative course, and social fac-
tors. Because our study was retrospective, the exact reason
for the timing of discharge for the patients and the surgeon
to surgeon variability in approving dischargewas difficult to
determine. In the present series, 5 surgeons performed most
of the operations. Of the 5, 4 performed both VATS and
open resection, and 1 performed open resection exclusively.
When the results for the primary surgeons, who performed
surgery using one or both of these approaches, were ana-
lyzed, open resections were associated with a longer LOS
compared with VATS resections. Despite this finding, it is
important to recognize that the underlying reasons for the
hospital LOS are multifactorial and cannot be attributed
to a single factor such as the surgical approach alone. There-
fore, firm conclusions cannot be drawn regarding this issue
owing to the inherent limitations of a retrospective study.
Oncologic Outcomes
A recent systematic review of surgical resection for thy-
moma reported that the overall 5-year survival rate of pa-
tients with stage I and stage II thymoma ranged from
89% to 100% and 71% to 95%, respectively.10 That re-
view also concluded that the published evidence comparing
the outcomes of various surgical approaches, in particular,
minimally invasive approaches, was insufficient. Although
some reports have been published of thoracoscopic thymec-
tomy for nonthymoma MG, very few data describing the
outcomes for minimally invasive resection of thymoma
are available. In one of the few studies exploring VATS ap-
proaches for thymoma, Cheng and associates28 compared
VATS resection of stage II thymoma in 12 patients with
open resection in 10 patients. They found no significant dif-
ferences in the outcomes of either survival or recurrence
during follow-up.
In addition to the tumor characteristics,29 one of the
confounding variables in the evaluation of outcomes after
thymectomy is the use of adjuvant therapy. Adjuvant
radiotherapy is typically used for patients with stage II thy-
moma, although the value of adjuvant therapy has been
questioned.30 In the present series, no significant differ-
ences were present in the use of adjuvant therapy between
the groups undergoing minimally invasive versus open
resection.
Study Limitations
The present study had several limitations. These limita-
tions included those common to nonrandomized retrospec-
tive studies, such as the potential selection bias of the
treating surgeon. In addition, the study sample was small,
and few outcome events occurred. Although we did not
find any significant difference between the 2 arms in termsrdiovascular Surgery c Volume 141, Number 3 699
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required, because a full evaluation of the survival endpoints
will require greater maturity of time-to-event data. Thy-
moma is an indolent disease, and longer follow-up is needed
to determine the oncologic outcomes of VATS thymectomy.
In addition, the use of the minimally invasive VATS ap-
proach was started later than use of the open procedure;
thus, the VATS patients require additional observation for
follow-up equivalence.
CONCLUSIONS
To our knowledge, the present series is the largest pub-
lished report comparing the outcomes of a minimally inva-
sive thoracoscopic resection of thymoma with those of an
open technique. VATS resection of early-stage thymoma
appears feasible and safe and was associated with a shorter
hospital LOS. The oncologic outcomes also appear equiva-
lent in the open and VATS groups during intermediate-term
follow-up. Additional follow-up is required to evaluate the
long-term results of thoracoscopic thymectomy for early-
stage thymoma.
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Dr Nasser Altorki (New York, NY). I have a question for you. I
disagree with 4 of your 5 conclusions. I think to talk about onco-
logic validity in thymoma with anything that is less than 5 years,
or preferably 10 years, is probably not correct. Thirty six months
is just way too short of a follow-up to be able to tell that. How
did you follow-up those patients? How carefully did you follow-
up those patients?
Dr Pennathur.Well, we have acknowledged in our conclusions
that longer follow-up is required.We saw all of these patients in the
clinic typically about every 4 to 6months. Now, themyasthenia pa-
tients were also followed very closely by the neurologist, and that
follow-upwas actually a little bit closer, about 3months. So Iwould
say that the myasthenia patients were a little bit more closely fol-
lowed-up compared with the nonmyasthenic thymoma patients.
Dr Altorki. My concern is that I have seen some of those pa-
tients come after transpleural resections, and sometimes youery c March 2011
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Shave to enter the pleural space and they will come back 10 years
later, 12 years later, with pleural implants in the posterior gutters,
basically in both pleural spaces, and that is one reason that I have
found the video-assisted thoracoscopic surgery approach a little bit
intimidating, at least for me.
Dr Pennathur. Yes, I think your point is very valid. I agree that
we need longer follow-up, to fully evaluate the results, which we
have acknowledged in the conclusions. However, there is no series
in the literature to my knowledge evaluating outcomes comparing
a thoracoscopic approach to an open approach at this length of fol-
low-up (36 months), and that is what we have attempted to do.
Also, in terms of the pleural droplet metastasis which does occur
in thymoma, the thoracoscopic approach provides good visualiza-
tion. The first thing you do is explore the chest and we are able to
actually get a good view of the pleura space with the thoracoscopic
approach.
Dr Federico Venuta (Rome, Italy). I was reading your abstract
and I noted in the abstract that you reported 3 patients with positive
margins but in your presentation there was only 1 patient with
a positive margin in the thoracoscopic group.
Dr Pennathur.Yes. That is an error in the abstract. It is 1 patient
with a positive margin.
Dr Venuta. And if I may ask another question, how did you di-
vide these patients with the 2 approaches? How did you decide
who received the open approach and who received the thoraco-
scopic approach?
Dr Pennathur. This is certainly not a randomized study, so
there is clearly a selection bias in terms of the surgeon and the pa-
tient in deciding the approach. In general, if the thymoma is less
than about 5 cm or so, particularly in the early stage of performing
these thoracoscopic thymectomies, we preferred to do those thy-
momas that looked small and encapsulated. Some of them on final
pathology, however, had capsular invasion, putting them as a stage
II. When there was concern about invasion into adjacent structures
or bigger lesions, those were handled by an open approach. The
largest lesion in this series in the video-assisted thoracoscopic sur-
gery approach was 5.6 cm and the median was 3.6 cm. So I think it
is the size, the appearance on the CT scan, relationship to adjacent
structures, and, of course, there is a selection bias in terms of the
surgeon who is doing the case. This is a retrospective study. It’s
not a prospective randomized study.
Dr Venuta. What are your indications for postoperative radio-
therapy?
Dr Pennathur.Well, I know this is being debated. Dr Wright at
Massachusetts General had presented a series on the usefulness of
radiation for stage II and a similar series has been presented by Dr
Singhal from the University of Pennsylvania questioning the value
of radiation. In our institution, if it’s a stage II or higher, we give
consideration for radiation therapy. Other considerations for radi-
ation include positive margins and more advanced tumors. But I
think this is something is being questioned. The recurrences occur
many times in the pleura, as Dr Altorki pointed out, so radiating
them in the chest—the thymic bed—may not entirely be effective.The Journal of Thoracic and CaDr Raphael Bueno (Boston, Mass). Nice paper and I think it
will take time to figure out what the answer is. You had another pa-
rameter besides oncologic, which is the recurrence of myasthenia.
Did that differ in the 2 groups?
Dr Pennathur.No, it did not differ. The bottom linewas that the
Osserman score showed a significant improvement in both the
groups. Nine out of 11 patients with myasthenia improved. The
Osserman score had a mean drop of negative 2, which is an overall
improvement. We did not find significant differences between the
surgical groups.
Dr Michael Jaklitsch (Boston, Mass). My personal inhibition
against doing a thoracoscopic thymectomy for thymoma is from
my personal experience, in that in dissecting out the gland, I can
see micro-defects in the capsule of the gland, and what makes
you stage I is having that gland intact. I have used a variety of tech-
niques, but I can see these little nicks, which I do not get with a par-
tial sternotomy. Am I different from you and you have a technique
that you can get the gland out without capsular nicks, or am I like
you and we are both getting capsular nicks but you are showing me
oncologically that those nicks do not matter?
Dr Pennathur.Well, I think that there are various ways of mo-
bilizing the thymus, and oneway, for example, described byDrAu-
gasthian at the Society of Thoracic Surgeons, which is similar to
ours, is we do not handle the tumor first. Try to go toward more
of the normal thymus, mobilize, and create the plane before obvi-
ously going where the mass is and before trying to mobilize the
mass initially. So, if you start from the normal tissue and start mo-
bilizing from there, that helps. The other thing that we have done
over the years with the evolution of the technique is that we have
used a bilateral approach. You get a very good look at the left
side. We start mobilization on the left side, and then as we move
along, the patient is placed supine, which also helps with easy con-
version, if needed; and then we go to the right side, and, again, you
can take from the normal tissue and then mobilize it, and then you
will be able to potentially avoid some of those nicks. But it can be
a problem. One has to handle the capsule very carefully.
Dr Thomas Rice (Cleveland, Ohio). Beyond the short follow-
up and the few events, you have to ask: Are these comparable
groups? So when you come to doing your multivariable analysis
when you get enough events, even if you do not have enough pa-
tients, you should put the propensity score in the multivariable
analysis to see if it is a fair comparison. It probably is not.
Dr Pennathur. Dr Rice, thank you for your comments. Yes, we
can certainly consider doing that—trying to adjust for the various
variables. One thing we found was that size was bigger in the open
group.
Dr Nasser Altorki (New York, NY). Perhaps you have done it
already, but let me just make a pitch for the partial sternal splits,
which are ideally suited for small thymomas of the superior medi-
astinum, because I do agree that your length of stay can probably
be shortened.
Dr Pennathur.Yes. Thanks for your comments. I want to thank
the Society for the opportunity to present this paper.rdiovascular Surgery c Volume 141, Number 3 701
